Parkinson's Disease Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Pfizer, AbbVie, Amneal, PharmaTwoB, Annovis Bio, Inhibikase, Neuraly, Peptron, Biogen, AstraZeneca, Roche, Alexza, MeiraGTx, BioVie, and Takeda

The Parkinson's Disease market is witnessing dynamic evolution, fueled by ongoing research into disease mechanisms and novel therapeutic approaches. Advancements in deep brain stimulation, gene therapy, and disease-modifying treatments are reshaping the landscape of Parkinson's care, offering improved symptom management and disease progression. Additionally, patient-centric initiatives and advocacy efforts are driving greater awareness and access to innovative therapies, promising a brighter future for individuals living with Parkinson's Disease.

DelveInsight's "Parkinson's Disease Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Parkinson's Disease Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Parkinson's Disease therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Parkinson's Disease treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Parkinson's Disease: An Overview
Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement.

The cause of Parkinson's disease remains unknown, but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. The majority of cases are thought to arise sporadically, although up to 20% of people with Parkinson's disease also have a first-degree relative with Parkinson's disease.

Classic presenting features of Parkinson's disease include motor symptoms, such as bradykinesia, rigidity, rest tremor, and postural instability. However, non-motor symptoms, such as depression, cognitive impairment, pain, and autonomic disturbances, are also often present, and they can severely affect a patient's quality of life.

Parkinson's Disease Market Key Facts
• The total Parkinson's disease market size in the 7MM was approximately USD 2,936.3 million in 2022 and is projected to increase during the forecast period (2023-2032).
• According to DelveInsight's estimates, among the 7MM, the US had the largest Parkinson's disease market share, with a revenue of USD 1,760.7 million in 2022. The Parkinson's disease market size in the US will increase at a significant CAGR due to increasing awareness of the disease and the growth of emerging and existing Parkinson's disease therapies.
• In 2022, among the 7MM, the total Parkinson's disease market share in EU4 and the UK was approximately 31%. Among EU4 and the UK countries, Germany accounted for the maximum Parkinson's disease market size in 2022, while Italy occupied the bottom of the ladder.
• Japan accounted for the third-largest Parkinson's disease market size among the 7MM, with a revenue of approximately USD 276.5 million in 2022, expected to increase during the forecast period.
• In 2022, the total diagnosed prevalent cases of Parkinson's disease were estimated to be approximately 2,539,400 cases in the 7MM. These cases are projected to increase during the forecast period (2023-2032).
• In 2022, EU4 and the UK accounted for nearly 47% of the total diagnosed prevalent cases of Parkinson's in the 7MM. These cases are anticipated to increase by 2032.
• In 2022, among the 7MM, Japan had the fourth-highest diagnosed prevalent cases of Parkinson's disease, accounting for approximately 8% of the total cases in the 7MM.

Get a Detailed Overview of the Evolving Parkinson's Disease Market Trends @
https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Parkinson's Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Parkinson's Disease therapies in the market. It also provides a detailed assessment of the Parkinson's Disease market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Parkinson's Disease drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Parkinson's Disease Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Parkinson's Disease Epidemiology
The epidemiology section covers detailed insights into the historical, and current Parkinson's Disease patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Parkinson's Disease Epidemiology Segmented as -
• Total diagnosed prevalent cases of Parkinson's disease
• Gender-specific diagnosed prevalent cases of Parkinson's disease
• Age-specific diagnosed prevalent cases of Parkinson's disease
• Stage-specific diagnosed prevalent cases of Parkinson's disease

Get Key Insights Into the Evolving Parkinson's Disease Epidemiology Trends @
https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Parkinson's Disease Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson's Disease market or expected to be launched during the study period. The analysis covers the market share by Parkinson's Disease drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Parkinson's Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Parkinson's Disease Market @
https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Parkinson's Disease Therapeutics Assessment
There is no standard treatment for Parkinson's disease. Treatment for each person with Parkinson's disease is based on their symptoms. There are many medications available to treat Parkinson's symptoms, although none yet reverse the disease's effects. It is common for people with Parkinson's disease to take a variety of these medications - all at different doses and at different times of day - to manage symptoms.

Anti-Parkinson's agents currently include levodopa dopamine agonists, MAO-B inhibitors, COMT-Inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists. The main goal of these medications is to control/reduce motor symptoms or the symptoms that affect movement in people with Parkinson's disease.

The earliest medications used in Parkinson's disease blocked brain receptors for acetylcholine (a nervous system neurotransmitter) called anticholinergics. Trihexyphenidyl (formerly available as Artane) and benztropine (Cogentin) are the two most common anticholinergics prescribed in Parkinson's disease. Carbidopa/levodopa/entacapone (Stalevo) is a combination drug which includes entacapone and levodopa in one pill. It is more convenient compared with carbidopa/levodopa + entacapone taken separately. Amantadine has become a useful adjunctive medication in people with advanced Parkinson's disease and motor fluctuations.

The increasing prevalence of Parkinson's disease and the expected launch of novel therapies during the study period will likely drive market growth. A few of the major market players in the Parkinson's disease market include AbbVie, Pharma Two B, Mitsubishi Tanabe Pharma, Takeda Pharmaceuticals, Amneal Pharmaceutical, and Praxis Precision Medicines. Strategic partnerships, and market access strategies play a vital role in achieving the market potential of new therapies.

Several major pharma and biotech companies are actively engaged in developing therapies for Parkinson's disease. Among them, several companies have advanced their drug candidates for Parkinson's disease to the most advanced stage of clinical development, namely Phase III trials. One such company is Cerevel Therapeutics, distinguished for its dedication to advancing innovative treatments for this neurodegenerative disorder. These companies collectively underscore a robust landscape of research and development efforts aimed at addressing the complex challenges posed by Parkinson's disease and improving the quality of life for patients worldwide.

Leading Companies in the Parkinson's Disease Therapeutics Market Include
Some of the prominent players in the Parkinson's Disease Therapeutics Market include Supernus Pharmaceuticals, Britannia Pharmaceutical, Cerevel Therapeutics, Pfizer, AbbVie, Amneal Pharmaceuticals, PharmaTwoB, Mitsubishi Tanabe Pharma (NeuroDerm), Annovis Bio, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio Inc., Anavex Life Sciences Corp, Alexza Pharmaceuticals Inc., PharmaTwoB Ltd., MeiraGTx LLC, BioVie Inc., Takeda Pharmaceuticals, and others.

Emerging and Marketed Parkinson's Disease Therapies Covered in the Report Include
• Tavapadon: Cerevel Therapeutics/Pfizer
• ABBV-951 (foscarbidopa/foslevodopa): AbbVie
• Buntanetap (ANVS401/posiphen): Annovis Bio
• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron
• BIIB094: Biogen
• P2B001 (extended-release pramipexole and rasagiline): Pharma Two B
• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/ Britannia Pharmaceutical
• XADAGO/EQUFINA (safinamide): Newron Pharmaceuticals/Zambon/Supernus Pharmaceuticals/Eisai
• NOURIANZ/NOURIAST (istradefylline): Kyowa Kirin
• DUOPA/DUODOPA (carbidopa and levodopa-ES): AbbVie
• INBRIJA (levodopa): Acorda Therapeutics/Esteve Pharmaceuticals
And Many Others

Learn More About the Emerging Therapies and key Companies in the Parkinson's Disease Therapeutics Market @
https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Parkinson's Disease Competitive Intelligence Analysis
4. Parkinson's Disease Market Overview at a Glance
5. Parkinson's Disease Background and Overview
6. Parkinson's Disease Patient Journey
7. Parkinson's Disease Epidemiology and Patient Population
8. Parkinson's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Parkinson's Disease Unmet Needs
10. Key Endpoints of Parkinson's Disease Treatment
11. Parkinson's Disease Marketed Products
12. Parkinson's Disease Emerging Therapies
13. Parkinson's Disease Seven Major Market Analysis
14. Attribute Analysis
15. Parkinson's Disease Market Outlook (7 major markets)
16. Parkinson's Disease Access and Reimbursement Overview
17. KOL Views on the Parkinson's Disease Market.
18. Parkinson's Disease Market Drivers
19. Parkinson's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.